methoxy polyethylene glycol-epoetin beta (Mircera) Report issue

Biologics Recombinant protein Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Methoxy polyethylene glycol-epoetin beta, sold under the brand name Mircera, is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anaemia associated with chronic kidney disease. It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$115.9306 - $1044.5539
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cera | cera (erythropoietin receptor activator) | continuous erythropoietin receptor activator | epo beta | epoetin beta | epoetin-beta | epoetin beta pegol | epoetin beta rdna | epoietin beta | methoxy polyethylene glycol epoetin beta | methoxy polyethylene glycol-epoetin beta | methoxy polyethylene glycol-epoetin-beta | mircera | pegylated epoetin beta | pegzerepoetin alfa | r744 | ro0503821

Organizations (23)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (2)


 

Anemia

Renal Insufficiency, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Anemia ()

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Dialysis (Phase 3)

Hemodialysis, Home (Phase 3)

Hepatitis C, Chronic (Phase 4)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Neoplasms (Phase 2)

Malnutrition (Phase 4)

Myocardial Infarction (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Reticulocyte Count (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 84
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue